First immunotherapy for mesothelioma on the horizon, early research suggests – Science Daily
MesotheliomaHelp.org (blog) |
First immunotherapy for mesothelioma on the horizon, early research suggests
Science Daily Early findings from an ongoing phase II clinical trial in France, MAPS-2, show that immunotherapy may slow the growth of MPM after relapse. At 12 weeks, cancer had not worsened in 44% of patients who received nivolumab (Opdivo) and in 50% of those who … UK Mesothelioma Clinical Trial Tests Another Immunotherapy Option for Mesothelioma Patients |
